Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

8.470 +0.540 (+6.81%)
Streaming Delayed Price Updated: 2:45 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 569,440
Open 8.050
Bid (Size) 8.460 (4)
Ask (Size) 8.480 (12)
Prev. Close 7.930
Today's Range 7.940 - 8.490
52wk Range 2.410 - 12.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
From Mind Medicine Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets

Performance

YTD
+133.98%
+133.98%
1 Month
+15.08%
+15.08%
3 Month
-2.42%
-2.42%
6 Month
+121.73%
+121.73%
1 Year
+91.63%
+91.63%

More News

Read More
3 Psychedelic Stocks to Ride to the Moon and Beyond
Via InvestorPlace
Exposures Product Safety
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Via Talk Markets
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
From Mind Medicine Inc.
Via Business Wire
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Mind Medicine Inc.
Via Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine
Via Business Wire
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What's Going On With MindMed And Psychedelic Stocks?
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
MindMed to Participate in June Conferences
From Mind Medicine Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Via InvestorPlace
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.